The company's main focus is on developing drugs to treat a variety of severe skin disorders. Their lead compound, SCENESSE, helps prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP) by increasing melanin levels in the skin and providing protection against harmful UV radiation. SCENESSE has successfully completed Phase II and III trials in the US and Europe and has received marketing authorization from the European Commission for use in adults with EPP. Clinuvel Pharmaceuticals operates in Europe, the US, and Singapore, aiming to prevent symptoms of skin diseases caused by UV radiation exposure and promote repigmentation of the skin in depigmentation disorders. The drug is administered through a subcutaneous dissolving implant.